Jing Xie, PhD, MS, Joins MDIC as Vice President, Clinical Affairs

Former Vice President, Global Clinical Affairs, Zimmer Biomet

Life Science Partner recruited Jing Xie, PhD, MS, former Vice President, Global Clinical Affairs for Zimmer Biomet to become the Medical Device Innovation Consortium’s (MDIC) first Vice President, Clinical Affairs.

MDIC is the first-ever public-private partnership (PPP) created with the sole objective of advancing medical device regulatory science to expedite development, assessment, and review of innovative medical technologies. The overall mission of the MDIC is to support the FDA’s vision to achieve first in the world patient access in the US and to assure the safety and effectiveness of medical devices through the Total Product Life Cycle.

Xie takes on her new role at the MDIC after having oversight of approximatively 300 clinical projects worldwide for Zimmer Biomet. She possesses a highly successful track record in the orthopedic industry for delivering on objectives, while maintaining effective collaboration with internal and external stakeholders.

“With a global understanding around clinical trial management including data integration for regulatory agencies across the US, Europe and Asia, Xie is a well-seasoned leader to execute the clinical affairs initiatives at the MDIC,” states Tom Callaway, MD, Founder and President of Life Science Partner.

Jing Xie earned her Bachelor of Science Degree in Analytical Chemistry from Xiamen University in China and completed her PhD in Materials Science from the University of Alabama. She holds an MS in Computer Science from Purdue University and an MS in Chemistry from the University of Alabama.



Francis Ota, MBA, Joins Lineagen as Chief Financial Officer

Former Executive Vice President, Finance MDxHealth

Life Science Partner recruited Francis Ota to become the Chief Financial Officer at Lineagen, an innovative genetics diagnostics company for neurodevelopmental disorders. Ota joins Lineagen after serving as the Executive Vice President of Finance for MDxHealth, a publically owned Belgium based diagnostic company with a US CLIA lab that develops epigenetic tests for cancer assessments.

During his tenure at MDxHealth, Ota played a key role in generating profitable growth, raising capital and negotiating M&A transactions. Earlier in his career he held financial leadership roles at Focus Diagnostics (acquired by Quest), QUAD Research, and Medtronic among others.

“As a global leader in finance, Ota has overseen the financial management of a CLIA laboratory from rapid growth through exit via acquisition,” states Tom Callaway, MD, President of Life Science Partner. “With his solid understanding of the reimbursement and revenue management challenges of a CLIA lab, Ota will serve as a critical member of Lineagen’s leadership team.”

Ota earned his Bachelor of Science Degree in Finance and International Business from the University of Colorado and his MBA from the University of California.

Judi Jaeger Joins Beckman Coulter as Director, Global Clinical Affairs

Former Vice President, Clinical Affairs at Elixir Medical

Life Science Partner has recruited Judi Jaeger to become Director, Global Clinical Affairs at Beckman Coulter reporting to Kim Oleson, Vice President of Clinical Affairs for Danaher’s Life Sciences and Diagnostics Platform.

“With first-hand leadership experience in the clinical development of two world-leading Class III devices and the ability to build and lead global teams, Jaeger’s scientific background in complex technologies and the regulatory intricacies will set her up to thrive and deliver at Beckman Coulter,” states Tom Callaway, MD, President and Founder of Life Science Partner.

During her clinical career, Jaeger was a critical part of Medtronic’s clinical team’s success in getting the Resolute product approved globally as well serving as key role for the worldwide approval of Johnson & Johnson/Cordis’ Cypher coated stent.

Jaeger earned her Bachelor of Arts Degree as a Psychology Major from Rutgers University in 1986.



Yanshan Ma, MD, PhD, Joins Allergan As Senior Director, Medical Safety Physician

Former Senior Director, Global Safety Officer at The Medicines Company

Life Science Partner recruited Yanshan Ma, MD, PhD, to become Senior Director, Medical Safety Physician, Internal Medicine and Infectious Diseases for Allergan.  In her new role Dr. Ma will be responsible for the group’s safety strategy, pharmacovigilance and medical risk management.

Dr. Ma joins Allergan after leading a cross-functional safety management team at The Medicines Company where she was responsible for ensuring accurate safety evaluation and signal detection.  She’s been a key member in the growth of The Medicines Company.

“Dr. Ma has hands-on leadership experience of both small groups and matrix organizations of physicians and safety scientists,” commented Tom Callaway, MD, Founder and President of Life Science Partner.  “She has the work ethic and pharmacovigilence knowledge that will fit nicely with the entrepreneurial environment of Allergan.”

Dr. Ma earned her PhD in Biochemistry from East Tennessee State University’s James E. Quillen College of Medicine and her MD from Sun Yat-sen University of Medical Sciences in China.


Bob Wassman, MD, Recruited to become Chief Medical Officer for Lineagen

Former Chief Medical Officer Rosetta Genomics Read more

Gloria Matthews, DVM, Joins Histogenics as Chief Medical Officer

Former Senior Director, Research and Development At Genzyme/Sanofi Read more

Upayan SenGupta, MBA, Recruited to Become Vice President, General Manager, Health Sciences for Underwriters Laboratories

Former Director, Global Segmentation Program, GE Healthcare

Read more

Barb DeBaun, RN, MSN Recruited to Vestagen as Consulting Vice President, Clinical Affairs

Improvement Advisor for Cynosure Health Joins Vestagen

Read more

Jim Schneider, JD, Joins American Medical Systems as Manager of Compliance

Former Senior Business Process Analyst, Global Compliance at Boston Scientific

Read more